Valneva SE American Depositary Shares (VALN) Stock Price

VALNStock

$5.61−39.30%52W

Market Cap$531.96M

P/E—

PEG Ratio—

Div yield—

Beta0.72

VALN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-12.68%

Price vs S&P 500 (4W)-10.38%

VGM Score57.47

Book Value / Share (Quarterly)$0.69

P/TBV (Annual)7.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-21.52%

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-42.80%

Gross Margin (TTM)23.83%

Net Profit Margin (TTM)-48.58%

EPS (TTM)$-1.22

10-Day Avg Trading Volume0.36M

EPS Excl Extra (TTM)$-1.22

Revenue Growth (5Y)9.62%

EPS (Annual)$-0.77

ROI (Annual)-36.75%

Gross Margin (Annual)38.66%

Net Profit Margin (5Y Avg)-39.98%

Cash / Share (Quarterly)$0.71

Revenue Growth QoQ (YoY)-37.23%

ROA (Last FY)-28.88%

Revenue Growth TTM (YoY)14.56%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)-60.52%

Operating Margin (TTM)-34.88%

Cash Flow / Share (Annual)$-0.37

P/B Ratio4.62x

P/B Ratio (Quarterly)6.05x

Net Income / Employee (Annual)$-186,337

EV / Revenue (TTM)1.83x

Net Interest Coverage (TTM)-2.56x

ROA (TTM)-37.47%

EV / EBITDA (TTM)23.33x

EPS Incl Extra (Annual)$-0.77

Current Ratio (Annual)2.38x

Quick Ratio (Quarterly)1.85x

3-Month Avg Trading Volume0.67M

52-Week Price Return-39.30%

Revenue / Employee (TTM)$490,312

Tangible BV / Share (Quarterly)$0.54

P/S Ratio (Annual)2.81x

Asset Turnover (Annual)0.44x

52-Week High$5.78

Operating Margin (5Y Avg)-28.31%

EPS Excl Extra (Annual)$-0.77

CapEx CAGR (5Y)-25.46%

Tangible BV CAGR (5Y)14.81%

26-Week Price Return-2.78%

Quick Ratio (Annual)1.85x

13-Week Price Return18.26%

Total Debt / Equity (Annual)1.95x

Current Ratio (Quarterly)2.38x

Enterprise Value$659.85M

Revenue / Share Growth (5Y)-3.10%

Asset Turnover (TTM)0.71x

Book Value / Share Growth (5Y)-6.39%

Revenue / Employee (Annual)$282,536

Inventory Turnover (Annual)2.06x

Pretax Margin (Annual)-65.34%

Cash / Share (Annual)$0.71

3-Month Return Std Dev58.18%

Gross Margin (5Y Avg)34.55%

Net Income / Employee (TTM)$-309,925

EBITDA CAGR (5Y)41.51%

ROE (Last FY)-108.50%

Net Interest Coverage (Annual)-3.10x

EPS Basic Excl Extra (Annual)$-0.77

P/FCF (TTM)35.02x

Receivables Turnover (TTM)10.20x

Total Debt / Equity (Quarterly)1.95x

EPS Incl Extra (TTM)$-1.22

Receivables Turnover (Annual)5.54x

ROI (TTM)-47.24%

P/S Ratio (TTM)1.62x

Pretax Margin (5Y Avg)-39.29%

Revenue / Share (Annual)$1.17

Tangible BV / Share (Annual)$0.54

Forward P/E31.43x

Price vs S&P 500 (52W)-54.83%

Year-to-Date Return-32.25%

5-Day Price Return-4.69%

EPS Normalized (Annual)$-0.77

ROA (5Y Avg)-17.08%

Net Profit Margin (Annual)-65.95%

Month-to-Date Return-7.05%

Cash Flow / Share (TTM)$-0.22

EBITD / Share (Annual)$-0.52

Operating Margin (Annual)-46.98%

LT Debt / Equity (Annual)1.52x

ROI (5Y Avg)-26.83%

LT Debt / Equity (Quarterly)1.52x

EPS Basic Excl Extra (TTM)$-1.22

P/TBV (Quarterly)7.66x

P/B Ratio (Annual)6.05x

Inventory Turnover (TTM)2.97x

Pretax Margin (TTM)-47.95%

Book Value / Share (Annual)$0.69

Price vs S&P 500 (13W)15.58%

Beta0.72x

P/FCF (Annual)4.14x

Revenue / Share (TTM)$1.91

ROE (TTM)-109.23%

52-Week Low$2.28

vGradeC

gGradeC

mGradeB

vgmGradeC

VALN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.09	-$0.44	-395.44%(-$0.36)
Q1 2026	May 13, 2026	-$0.24	-$0.47	-100.74%(-$0.24)
Q4 2025	Mar 17, 2026	—	-$0.74	—
Q3 2025	Nov 20, 2025	-$0.29	-$0.67	-130.73%(-$0.38)
Q2 2025	Aug 12, 2025	-$0.22	-$0.18	+15.45%(+$0.03)

VALN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.08

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VALNValneva SE American Depositary Shares	C	C	B	1.6x	14.6%	23.8%	—	$5.61
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Valneva SE American Depositary Shares

Valneva SE is a vaccine company with marketed products for travelers, including IXIARO, DUKORAL, and IXCHIQ. The company generates revenue primarily from vaccine sales while maintaining development programs for new vaccine candidates and COVID-19 vaccine initiatives. Additional revenue streams include technology licensing and manufacturing services.